Results from a phase III trial (GRID) evaluating regorafenib in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics

Author(s):
Bauer, S.; Joensuu, H.; Casali, P.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Rutkowski, P.; Gelderblom, H.; Hohenberger, P.; Leahy, M.; Mehren, M. von; Badalamenti, G.; Blackstein, M.; Cesne, A. le; Schoffski, P.; Maki, R.G.; Xu, J.; Nishida, T.; Kappeler, C.; Kuss, I.; Demetri, G.D.
Published
2013
Publication type
Article / Letter to editor
Date issued
2013-10-31
Language
English
Is part of
Onkologie (2013), Vol. 36, p. 180-181
hdl
1887/100062